Litigation

Recent Posts

Supreme Court Grants Certiorari In Patent Dispute Over Hatch-Waxman Provision
Posted on 27 Jun 2011 by Melissa Ritti

WASHINGTON, D.C. - (Mealey's) The U.S. Supreme Court will review the Federal Circuit U.S. Court of Appeals' ruling, in a case of first impression, that the counterclaim provision of the Hatch-Waxman Act is available "only if the listed patent... Read More

Tags: counterclaim provision , Federal Circuit , Novo Nordisk , Caraco Pharmaceutical Laboratories , Hatch-Waxman Act , Patent , Litigation , Caraco Pharmaceutical v. Novo Nordisk A/S , Sun Pharmaceuticals Industries , . Supreme Court

Novo Nordisk Pays $26.7 Million To Settle Off-Label, Improper Payment Lawsuits
Posted on 13 Jun 2011 by Tom Moylan

(Mealey's) Danish drug and biologics maker Novo Nordisk will pay a total of $26.7 million to settle separate False Claims Act lawsuits that include allegations that it paid military doctors to use a hemophilia drug off-label on wounded soldiers and... Read More

Tags: False Claims Act , hemophilia drug , off-label use , Ian Black , Novo Nordisk , Oscar Montier , United States of America v. Novo Nordisk , Litigation , lawsuit , NovoSeven

Amylin Sues Eli Lilly Over Diabetes Drug Development Deal
Posted on 17 May 2011 by LexisNexis Litigation Resource Community Staff

INDIANAPOLIS - (AP) Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim... Read More

Tags: drugs , linagliptin , Novo Nordisk , Food and Drug Administration , drugmaker , Eli Lilly , Type 2 diabetes , exenatide , Tradjenta , Amylin , Byetta , Boehringer Ingelheim , diabetes drugs , drug development , Merck , Litigation , lawsuit , Bristol-Myers Squibb , Bydureon